Literature DB >> 26589872

Histological tumor typing in the age of molecular profiling.

Frederick Klauschen1, Daniel Heim2, Albrecht Stenzinger3.   

Abstract

Clinical oncology and pathological diagnostics regard cancer as an organ- and tissue-specific disease. Comprehensive mutational profiling information from next-generation sequencing projects may be used to study to what extent the anatomic tumor classifications relate to the observed molecular profiles. Here, we review data that show substantial genetic similarities across major anatomic cancer types and that propose novel tumor classifications based on mutational profiling. Although these studies provide important insight into molecular tumor properties and some even propose novel tumor classification systems, current clinical evidence is lacking that genetic tumor profiling is sufficient to replace histological tumor typing. Recent studies rather show that targeted treatments efficaceous in one tumor type are not necessarily successful in another despite the presence of the same (actionable) mutations. We discuss the implications of the observed complex mutational tumor profiles for targeted therapy selection and future trial design in precision oncology.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Basket trials; Cancer; Clinical trials; Molecular pathology; Mutational profiling; Next generation sequencing; Precision oncology; Systems medicine

Mesh:

Year:  2015        PMID: 26589872     DOI: 10.1016/j.prp.2015.08.001

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  2 in total

1.  Supervised non-negative matrix factorization methods for MALDI imaging applications.

Authors:  Johannes Leuschner; Maximilian Schmidt; Pascal Fernsel; Delf Lachmund; Tobias Boskamp; Peter Maass
Journal:  Bioinformatics       Date:  2019-06-01       Impact factor: 6.937

2.  NXPH4 Used as a New Prognostic and Immunotherapeutic Marker for Muscle-Invasive Bladder Cancer.

Authors:  Zhiming Gui; Xiaoling Ying; Chunxiao Liu
Journal:  J Oncol       Date:  2022-10-04       Impact factor: 4.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.